The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Improvement of Coronary Flow Velocity Reserve with Telmisartan in Patients with Autosomal-Dominant Polycystic Kidney Disease

Authors: Sabahat Alisir, MD, Kultigin Turkmen, MD, Nilufer Alpay, MD, Ali Elitok, MD, Huseyin Oflaz, MD, Bora Uslu, MD, Arif Cimen, MD, Erdem Kasikcioglu, MD, Fatih Tufan, MD, Tevfik Ecder, MD

Abstract


Objectives: Endothelial dysfunction (ED) has been reported in patients with autosomal-dominant polycystic kidney disease (ADPKD). Coronary flow velocity reserve (CFVR) is a noninvasive test showing endothelial function of epicardial coronary arteries and coronary microcirculatory function. The aim of this study was to investigate the effect of the angiotensin receptor blocker, telmisartan, on CFVR in patients with ADPKD.


Methods: Thirteen patients with ADPKD and well-preserved renal function and 22 healthy controls were included in the study. CFVR was measured at baseline and after dipyridamole infusion by echocardiography. CFVR was calculated as the ratio of hyperemic to baseline average peak diastolic velocities. After the baseline evaluation of CFVR, patients started telmisartan at a dose of 80 mg/day and were followed for 12 months. CFVR was remeasured after 6 and 12 months of therapy.


Results: Patients with ADPKD had significantly lower CFVR compared to healthy subjects. CFVR increased significantly after 6 months and 12 months of telmisartan therapy (P = 0.001) in patients with ADPKD.


Conclusion: One year of telmisartan therapy significantly improved CFVR in patients with ADPKD. This finding suggests that the stimulation of the renin-angiotensin-aldosterone system contributes to the ED in these patients.



This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic Kidney Disease in Schrier RW (ed): Diseases of the Kidney and Urinary Tract. Philadelphia, PA, Lippincott Williams &Wilkins, 2007, ed 8, pp 502–539.
 
2. Fick GM, Johnson AM, Hammond WS, et al. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048–2056.
 
3. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009;5:221–228.
 
4. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12:194–200.
 
5. Chapman AB, Johnson A, Gabow PA, et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091–1096.
 
6. Harrap SB, Davies DL, Macnicol AM, et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501–508.
 
7. Barrett BJ, Foley R, Morgan J, et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:1118–1123.
 
8. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001;87:3C–9C.
 
9. Hirsch AT, Pinto YM, Schunkert H, et al. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D–30D; discussion 30D–32D.
 
10. Wolf G. Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant 1999;14 (suppl 1):42–44.
 
11. Chapman AB, Johnson AM, Rainguet S, et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292–1297.
 
12. Valero FA, Martinez-Vea A, Bardají A, et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1020–1026.
 
13. Oflaz H, Alisir S, Buyukaydin B, et al. Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:2244–2249.
 
14. Wang D, Iversen J, Wilcox CS, et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381–1388.
 
15. Kocaman O, Oflaz H, Yekeler E, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004;43:854–860.
 
16. Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998;97:1557–1562.
 
17. Rigo F. Coronary flow reserve in stress-echo lab. From pathophysiologic toy to diagnostic tool. Cardivasc Ultrasound 2005;3:8.
 
18. Turkmen K, Oflaz H, Uslu B, et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 2008;3:986–991.
 
19. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343:824–827.
 
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
 
21. Saggar-Malik AK, Missouris CG, Gill JS, et al. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. BMJ 1994;309:1617–1618.
 
22. Bardají A, Vea AM, Gutierrez C, et al. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998;32:970–975.
 
23. Zeier M, Geberth S, Schmidt KG, et al. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993;3:1451–1457.
 
24. Lüscher TF. Endothelial dysfunction: the role and impact of the renin-angiotensin system. Heart 2000;84(suppl 1):i20–i22; discussion i50.
 
25. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257–1266.
 
26. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899–1906.
 
27. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948–954.
 
28. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186–193.
 
29. Skalidis EI, Parthenakis FI, Patrianakos AP, et al. Regional coronary flow and contractile reserve in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004;44:2027–2032.
 
30. Cecchi F, Olivotto I, Gistri R, et al. Coronary microcircular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027–1035.
 
31. Yokoyama I, Momomura S, Ohtake T, et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997;30:1472–1477.
 
32. Galiuto L, Sestito A, Barchetta S, et al. Noninvasive evaluation of flow reserve in the left anterior descending coronary artery in patients with cardiac syndrome X. Am J Cardiol 2007;99:1378–1383.
 
33. Kamezaki F, Tasaki H, Yamashita K, et al. Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker. Hypertens Res 2007;30:699–706.